Atrial fibrillation in outpatients with stable coronary artery disease : results from the multicenter RECENT study

Zielonka, Anna; Tkaczyszyn, Michał; Mende, Maciej; Nowak, Wojciech; Rekucki, Konrad; Soczomski, Przemysław; Zieliński, Michał; Pociupany, Robert; Wilkins, Arleta; Banasiak, Waldemar; Ponikowski, Piotr; Jankowska, Ewa A.

doi:10.20452/pamw.2709

Cited by 13 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most probably, however, the prevalence of atrial fibrillation will continue to increase with population aging. 20 In addition, Qvist et al 21 have suggested that despite the decrease in the number of hospitalizations due to the arrhythmia itself, the number of its complications, such as heart failure or stroke, is actually increasing. In contrast to atrial fibrillation, the hospitalization rate of patients diagnosed with any arrhythmia other than atrial fibrillation has increased over the years.…”

Section: Resultsmentioning

confidence: 99%

Causes of hospitalisation and prognosis in patients with cardiovascular diseases – secular trends 2006-2014. SILesian CARDiovascular (SILCARD) database covering a population of 4.6 million subjects

Gąsior¹,

Pres²,

Wojakowski³

et al. 2016

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Causes of hospitalisation and prognosis in patients with cardiovascular diseases – secular trends 2006-2014. SILesian CARDiovascular (SILCARD) database covering a population of 4.6 million subjects

Gąsior¹,

Pres²,

Wojakowski³

et al. 2016

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…Of note, recent studies have demonstrated that combined anticoagulant and antiplatelet therapy is independently associated with significantly increased risk for bleeding compared with anticoagulant therapy alone in AF patients 27 . Moreover, the antithrombotic treatment of AF may complicate coronary revascularization and related antiplatelet treatment 11 . Therefore, the attention must be directed towards preventing CAD at an early stage in order to improve the treatment and prognosis of AF, with more focus on the AMI risk stratification.…”

Section: Discussionmentioning

confidence: 99%

“…The CHADS 2 and CHA 2 DS 2 -VASc scores include similar risk factors for the development of CAD. Therefore, unsurprisingly, there have been recent reports about the two stroke risk scoring systems used to predict severity or even outcome of CAD 11 . Most previous studies mainly focused on AF after CAD and demonstrated AF adversely influences the outcomes in patients with CAD.…”

Section: Introductionmentioning

confidence: 99%

Predictive value of CHADS2 and CHA2DS2-VASc scores for acute myocardial infarction in patients with atrial fibrillation

Hui

Han

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The presence of acute myocardial infarction (AMI) confers a poor prognosis in atrial fibrillation (AF), associated with increased mortality dramatically. This study aimed to evaluate the predictive value of CHADS2 and CHA2DS2-VASc scores for AMI in patients with AF. This retrospective study enrolled 5140 consecutive nonvalvular AF patients, 300 patients with AMI and 4840 patients without AMI. We identified the optimal cut-off values of the CHADS2 and CHA2DS2-VASc scores each based on receiver operating characteristic curves to predict the risk of AMI. Both CHADS2 score and CHA2DS2-VASc score were associated with an increased odds ratio of the prevalence of AMI in patients with AF, after adjustment for hyperlipidaemia, hyperuricemia, hyperthyroidism, hypothyroidism and obstructive sleep apnea. The present results showed that the area under the curve (AUC) for CHADS2 score was 0.787 with a similar accuracy of the CHA2DS2-VASc score (AUC 0.750) in predicting “high-risk” AF patients who developed AMI. However, the predictive accuracy of the two clinical-based risk scores was fair. The CHA2DS2-VASc score has fair predictive value for identifying high-risk patients with AF and is not significantly superior to CHADS2 in predicting patients who develop AMI.

show abstract

“…The present study emphasised the role of the previous MI in maintaining stable anticoagulation. MI is an established risk factor for AF, with AF occurring in 6% to 21% of patients following MI [22,23]. The poor TTR control was an independent predictor of major adverse cardiovascular events including MI in a cohort of 627 AF patients on VKA patients followed by Pastori et al [24].…”

Section: Discussionmentioning

confidence: 99%

Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation

2017

View full text Add to dashboard Cite

(1-3). Proportions of patients with ≥ 2 points and 0-1 points in the SAMe-TT 2 R 2 score who had the time in therapeutic range (TTR) ≤ 70% were similar (61 [67%] vs. 63 [56%], p = 0.11). A modified score, involving medical history (myocardial infarction [MI] and chronic obstructive pulmonary disease [COPD], 1 point), statin treatment (1 point) and tobacco use (2 points) had a higher area under the curve (AUC) in patients on acenocoumarol compared to p = 0.042 (Cardiol J 2017; 24, 5: 477-483)

show abstract

Atrial fibrillation in outpatients with stable coronary artery disease : results from the multicenter RECENT study

Cited by 13 publications

References 9 publications

Causes of hospitalisation and prognosis in patients with cardiovascular diseases – secular trends 2006-2014. SILesian CARDiovascular (SILCARD) database covering a population of 4.6 million subjects

Causes of hospitalisation and prognosis in patients with cardiovascular diseases – secular trends 2006-2014. SILesian CARDiovascular (SILCARD) database covering a population of 4.6 million subjects

Predictive value of CHADS2 and CHA2DS2-VASc scores for acute myocardial infarction in patients with atrial fibrillation

Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation

Contact Info

Product

Resources

About